مفردات منهج كورسات طلبة الماجستير / أدوية وسموم

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **المادة /** الفصل الأول | | **الساعات** | | **الوحدات** | |
| **أدوية متقدم**  **Advance pharmacology**  **I** | | **نظري** | **عملي** | **3.5** | |
| **2** | **3** |
| **No.** | **المفردات subject** | | | | **weeks** |
|  | **pharmacokinetic** | | | | **3** |
|  | **Pharmacodynamic of drugs** | | | |
|  | **Receptors theory,type of response** | | | |
|  | **Drug Acting on the autonomic and somatic nervous system** | | | | **4** |
|  | **Autonomic nervous system** | | | |
|  | **Adrenergic agonist and antagonist** | | | |
|  | **Cholinergic pharmacology , Autonomic drugs** | | | |
|  | **Neuromuscular blocking agents** | | | |
|  | **Drugs acting on the central nervous system** | | | | **4** |
|  | **Central nervous system** | | | |
|  | **General anaesthesia , Inhalation & njectable anesthetics** | | | |
|  | **Opioid agonists and antagonists** | | | |
|  | **Tranquilizers α2 – adrenergic agonists and related drugs** | | | |
|  | **Local anesthetics** | | | |
|  | **Anticonvulsant drugs and Analeptic agents** | | | |
|  | **Drugs affecting animal behavior** | | | | **1** |
|  | **Drug acting on Cardiovascular system** | | | | **3** |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **المادة/ الفصل الثاني** | | **الساعات** | | **الوحدات** | |
| **أدوية متقدم**  **Advance pharmacology**  **II** | | **نظري** | **عملي** | **3.5** | |
| **2** | **3** |
| **No.** | **المفردات subject** | | | | **weeks** |
|  | **Drugs affecting on Digestive system** | | | | **2** |
|  | **Drugs affecting on Respiratory system.** | | | | **2** |
|  | **Drugs affecting on urinary system** | | | | **2** |
|  | **Antiarrhythmic agents** | | | | **3** |
|  | **Autacoids and anti-inflammatory drugs.** | | | |
|  | **Histamine , Serotonin and their antagonists.** | | | |
|  | **Peptides : angiotensin and kinins** | | | |
|  | **Prostaglandins, related factors and cytokines** | | | |
|  | **The analgesic , antipyretic , anti-inflammatory drugs** | | | | **2** |
|  | **Drugs affecting the reproductive system** | | | | **3** |
|  | **Drugs affecting the skin** | | | | **1** |

**Therapeutics**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **المادة / الفصل الثاني** | | **الساعات** | | **الوحدات** | |
| **علاج**  **Therapeutics** | | **نظري** | **عملي** | **3.5** | |
| **2** | **3** |
| **No.** | **المفردات subject** | | | | **weeks** |
|  | **Chemotherapeutic Drugs** | | | | **2** |
|  | **Antimicrobial therapy** | | | |
|  | **Classification of antibacterial** | | | |
|  | **Mechanism of resistance** | | | |
|  | **Inhibition of cell wall synthesis** | | | | **1.5** |
|  | **Inhibition of Protein synthesis** | | | | **3** |
|  | **Inhibition of Nucleic Acid Synthesis** | | | | **3** |
|  | **Folate antagonists** | | | |
|  | **Urinary tract antiseptic** | | | |
|  | **Combination of antibacterial** | | | |
|  | **Failure treatment with antibacterial** | | | |
|  | **Chemotherapy of protozoal infection** | | | | **3** |
|  | **Anticoccidal drugs** | | | |
|  | **Vitamine antagonists** | | | |
|  | **Babesiocidal drugs** | | | |
|  | **trypanocidal drugs** | | | |
|  | **Antithelmintic drugs** | | | |
|  | **Chemotherapy of worm infections** | | | | **2.5** |
|  | **Drugs acting on fluks** | | | |
|  | **Fascioliasis therapy** | | | |
|  | **Drugs acting of external parasite** | | | |
|  | **Antiseptic & disinfected** | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **المادة / فصل ثاني** | | **الساعات** | | **الوحدات** | |
| **سموم سريري**  **Clinical Toxicology** | | **نظري** | **عملي** | **3.5** | |
| **2** | **3** |
| **No.** | **المفردات subject** | | | | **weeks** |
|  | **Principles of toxicology** | | | | **3** |
|  | **Toxickinetic** | | | |
|  | **Toxicodynamic** | | | |
|  | **Dose–response relationships** | | | |
|  | **Types of toxic reactions** | | | | **2** |
|  | **Estimation of toxic substance** | | | |
|  | **Teratogenic study** | | | | **3** |
|  | **Chemical carcinogens** | | | |
|  | **Interactions between chemicals** | | | |
|  | **Incidence of acute poisoning** | | | | **2** |
|  | **Major sources of information on poisoning** | | | | **1** |
|  | **Prevention and treatment of poisoning** | | | | **1** |
|  | **Prevention of Further Absorption of Poison** | | | | **1** |
|  | **Elimination of the Poison** | | | | **2** |
|  | **Heavy metals** | | | |
|  | **Heavy-metal antagonists** | | | |
|  | **Radioactive heavy metals** | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **المادة / فصل ثاني** | | **الساعات** | | **الوحدات** | |
| **تقييم دوائي**  **Drugs Evaluation** | | **نظري** | **عملي** | **3.5** | |
| **2** | **3** |
| **No.** | **المفردات subject** | | | | **No. of weeks** |
| **No.** | **subject** | | | |
|  | **Elimination of the Poison** | | | | **4** |
|  | **Elimination Heavy-metal** | | | |
|  | **Methods of LD50 , ED50** | | | |
|  | **Teratogenic study** | | | |
|  | **Microbiological assay** | | | | **4** |
|  | **Disk Diffusion Test and Gradient Methodologies** | | | |
|  | **Macro- and Microdilution Methods of Antimicrobial** | | | |
|  | **Agar Dilution Susceptibility Testing** | | | |
|  | **Antifungal Susceptibility Testing** | | | |
|  | **Thin layer chromatography** | | | |
|  | **Bioautography** | | | |
|  | **Methods of plantsextraction** | | | | **4** |
|  | **Detection of phytochemical** | | | |
|  | **Test of reproductive drugs** | | | |
|  | **Evaluation of spermatogenesis** | | | |
|  | **Fertility index** | | | |
|  | **Mating index** | | | |

مفردات منهج كورسات طلبة الدكتوراه / أدويةوسموم

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **المادة / فصل اول** | | **الساعات** | | **الوحدات** | |
| **ادوية سريري**  **Clincal pharmacology** | | **نظري** | **عملي** | **3.5** | |
| **2** | **3** |
| **No.** | **المفردات subject** | | | |  |
| **No.** | **subject** | | | | **No. of weeks** |
|  | **Fluid therapy** | | | | **6** |
|  | **Treatment direehea in claves** | | | |
|  | **Treatment of mastitis** | | | |
|  | **Anti-inflammatory drugs and treatment of arthritis** | | | |
|  | **Drugs Acting on the Respiratory Organs Function** | | | |
|  | **Drug Use During Pregnancy and Lactation** | | | | **6** |
|  | **Female reproductive endocrinology** | | | |
|  | **Male reproductive endocrinology** | | | |
|  | **Anterior pituitary hormones and related drugs** | | | |
|  | **Posterior pituitary hormones** | | | |
|  | **Examination** | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **المادة / فصل اول** | | **الساعات** | | **الوحدات** | |
| **تحليلات صيدلانية**  **Pharmaceutical analysis** | | **نظري** | **عملي** | **3.5** | |
| **2** | **3** |
| **No.** | **المفردات subject** | | | | **No. of weeks** |
| **No.** | **subject** | | | |
|  | **ELISA (Enzyme Linked Immunosorbent Assay )** | | | | **2** |
|  | **Polymerase Chain Reaction (PCR)** | | | | **2** |
|  | **Detection of antimicrobial drugs** | | | | **2** |
|  | **Antioxidantstest for Development** | | | |
|  | **Mast cell** | | | |
|  | **Thin layer chromatography** | | | | **6** |
|  | **HPLC analysis** | | | |
|  | **Hormone detection** | | | |
|  | **Examination** | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **المادة / فصل ثاني** | | **الساعات** | | **الوحدات** | |
| **حركية دوائية**  **Pharmacokinetic** | | **نظري** | **عملي** | **3.5** | |
| **2** | **3** |
| **No.** | **المفردات subject** | | | | **No. of weeks** |
| **No.** | **subject** | | | |
|  | **Pharmacokinetic Processes** | | | | **4** |
|  | **Mechanisms of Passage Across Membranes** | | | |
|  | **ABSORPTION / BIOAVAILABILITY** | | | |
|  | **Determinants of Bioavalability/ Biovailability - AUC** | | | |
|  | **Distribution/ Volume of Distribution (V)** | | | | **4** |
|  | **Metabolism / Biotransformation** | | | |
|  | **Excretion/ Clearance/ Hepatic Excretion/ Renal Excretion** | | | |
|  | **Kinetics of Elimination / Determination of the Slope** | | | |
|  | **Rates of reaction / *zero-order* or *first-order*.** | | | |
|  | **One -compartment model / Two-compartment model** | | | |
|  | **Multicompartment model** | | | |
|  | **Kinetics following a single drug dose/ Plasma half-life** | | | | **4** |
|  | **Repeated Dosing/ Monitoring of Plasma concentration** | | | |
|  | **Steady State** | | | |
|  | **Pharmacokinetics after extravascular administration. Bioavailability** | | | |
|  | **Bioequivalence / Hepatic clearance** | | | |
|  | **Examination** | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **المادة / فصل ثاني** | | **الساعات** | | **الوحدات** | |
| **علاج متقدم**  **Advance Therapeutics** | | **نظري** | **عملي** | **3.5** | |
| **2** | **3** |
| **No.** | **المفردات subject** | | | | **No. of weeks** |
| **No.** | **subject** | | | |
|  | **Antimycobacterial drugs** | | | | **4** |
|  | **mycobacterium** | | | |
|  | **Mycobacteriaassociatedwithhumandisease** | | | |
|  | **ClinicalPresentation/Diagnosis** | | | |
|  | **Antifungal Drugs** | | | | **4** |
|  | **Anti-viral drugs** | | | |
|  | **Structure of viruses** | | | |
|  | **The life cycle of Viruses** | | | |
|  | **Cancer** | | | |
|  | **The main categories of cancer include** | | | |
|  | **Carcinogens** | | | |
|  | **The Development of Cancer/ DNA of a normal cell** | | | | **4** |
|  | **Modalities of treatment./Radiation therapy** | | | |
|  | **Nuclear medicine / Chemotherapy** | | | |
|  | **Gene Therapy/ Categories of clinical gene transfer protocols** | | | |
|  | **Types of gene therapy/Ideal vector characteristics/Adenovirus** | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **المادة / فصل اول** | | **الساعات** | | **الوحدات** | |
| **تداخل دوائي**  **Drug interaction** | | **نظري** | **عملي** | **3.5** | |
| **2** | **3** |
| **No.** | **المفردات subject** | | | | **No. of weeks** |
| **No.** | **subject** | | | |
|  | **Pharmacokinetic interaction** | | | | **4** |
|  | **Absorption, Distribution** | | | |
|  | **Metabolism, Execration** | | | |
|  | **Food – drug interaction** | | | |
|  | **Pharacodynamic interaction** | | | | **4** |
|  | **Drug interactions toxicology** | | | | **4** |
|  | **Examination** | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **المادة / فصل ثاني** | | **الساعات** | | **الوحدات** | |
| **أدوية متقدم**  **Advance pharmacology III** | | **نظري** | **عملي** | **5** | |
| **2** | **6** |
| **No.** | **المفردات subject** | | | | **No. of weeks** |
| **No.** | **subject** | | | |
|  | **Diuretics** | | | | **4** |
|  | **Heart failure** | | | |
|  | **Antiarrhythmics** | | | |
|  | **Antianginal Drugs** | | | |
|  | **Anticoagulants and Antiplatelet Agents** | | | | **4** |
|  | **Drugs for Hyperlipidemia** | | | |
|  | **Pituitary and Thyroid** | | | |
|  | **Drugs for Diabetes** | | | |
|  | **Estrogens and Androgens** | | | |
|  | **Adrenal Hormones** | | | |
|  | **Drugs for Disorders of the Respiratory System** | | | | **4** |
|  | **Antihistamines** | | | |
|  | **Gastrointestinal and Antiemetic Drugs** | | | |
|  | **Drugs for Anemia** | | | |
|  | **Drugs for Dermatologic Disorders** | | | |
|  | **Examination** | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **المادة / فصل ثاني** | | **الساعات** | | **الوحدات** | |
| **سموم متقدم**  **Advance Toxicology** | | **نظري** | **عملي** | **3.5** | |
| **2** | **3** |
| **No.** | **المفردات subject** | | | | **No. of weeks** |
| **No.** | **subject** | | | |
|  | **Air pollution** | | | | **4** |
|  | **Water and soil pollution** | | | |
|  | **Geneticmutations** | | | | **4** |
|  | **CarcinogenicityCarcinogens** | | | |
|  | **Teratogeniceffects** | | | |
|  | **Pesticide poisoning** | | | | **4** |
|  | **In organic matterpoisoning** | | | |
|  | **Examination** | | | |